Kyrgyzstan struggles with deadly shortages of medicine

A man asks for donation for medicines in Bishkek, Kyrgyzstan. (AFP)
Short Url
Updated 30 July 2025
Follow

Kyrgyzstan struggles with deadly shortages of medicine

  • The five Central Asian countries are highly dependent on pharmaceutical imports and patients are often left to fend for themselves
  • Shortages, high prices and the poor quality of medicine affect many of the region’s 80 million inhabitants

BISHKEK: Like many people affected by serious illness in ex-Soviet Central Asia, Almagul Ibrayeva is having trouble finding medicine in her native Kyrgyzstan.
“Women are dying because of a lack of medicine,” Ibrayeva, who is in her 50s, told AFP.
In remission from breast cancer, Ibrayeva needs a hormone treatment called exemestane after having a mastectomy and her reproductive organs were removed.
She said she “often” faces difficulties.
“I order it from Turkiye or Moscow, where my daughter lives,” she said.
“There are many medicines that are simply unavailable here. The patient has to look themselves and buy them.”

Shortages, high prices and the poor quality of medicine affect many of the region’s 80 million inhabitants.
The five Central Asian countries are highly dependent on pharmaceutical imports and patients are often left to fend for themselves.
There are often cases of expired or adulterated medicine such as the cough syrup imported from India which killed 69 children in Uzbekistan in 2023.
The costs of high-quality medicine are often prohibitive.
“Some people sell their homes, their livestock, get into debt just to survive,” said Shairbu Saguynbayeva, a uterine cancer survivor.
She created a center called “Together to Live” in the Kyrgyz capital Bishkek which hosts women who have cancer, offering accommodation and help for treatment.
“Here they can get organized. When someone is receiving chemotherapy, they fall ill, not every loved one can handle it,” Saguynbayeva said.
Women at the center sew and sell traditional Kyrgyz ornaments — funding the treatment of 37 patients since 2019.
Saguynbayeva says she is grateful to the Kyrgyz state for “finally” starting to supply more medicine but says the quantity is still “meagre.”
One patient, Barakhat Saguyndykova, told AFP that she received “free anti-cancer medicine only three times between 2018 and 2025.”
At the National Oncology and Haematology Center, doctor Ulanbek Turgunbaev said that sourcing medicine was “a very serious problem for patients” even though medicine supply has increased.
He said the best way of reducing therapy costs was “early detection” of serious illnesses.

Material deficits and a shortage of 5,000 health professionals in Kyrgyzstan mean that the most urgent needs have to be addressed first.
President Sadyr Japarov has promised to eliminate corruption in the medical sector, which cost the health minister his job last winter.
While medicine factories have finally been opened, the situation in the short term remains complicated.
The Kyrgyz Chamber of Commerce and Industry said that “around 6,000 medicines could disappear from the market by 2026” because of the need to “re-register under the norms of the Eurasian Economic Union” — a gathering of former Soviet republics including Kyrgyzstan.
The government in 2023 created a state company called Kyrgyz Pharmacy which is supposed to centralize medicine requests and bring down prices, according to its head, Talant Sultanov.
But the organization has been under pressure because of a lack of results.
Sultanov said he hoped medicine prices could be lowered “by signing more long-term agreements with suppliers through purchases grouped on a regional basis” with other Central Asian countries.
Kyrgyz Pharmacy has promised steady supplies soon but many women in Bishkek are still waiting for medicine ordered through the company months ago.
Recently a mother of three “died simply because she did not receive her medicine in time,” Saguynbayeva said.
“It is better to save a mother than to build orphanages,” she said.


US allows oil majors to broadly operate in Venezuela, new energy investments

Updated 14 February 2026
Follow

US allows oil majors to broadly operate in Venezuela, new energy investments

  • Treasury Department issues general license allowing Chevron, BP, Eni, Shell and Repsol to operate oil and gas operations in Venezuela
  • Move is the most significant relaxation of sanctions on Venezuela since US forces captured and removed President Nicolas Maduro

WASHINGTON: The US ​eased sanctions on Venezuela’s energy sector on Friday, issuing two general licenses that allow global energy companies to operate oil and gas projects in the OPEC member and for other companies to negotiate contracts to bring in fresh investments. The move was the most significant relaxation of sanctions on Venezuela since US forces captured and removed President Nicolas Maduro last month.
The Treasury Department’s Office of Foreign Assets Control issued a general license allowing Chevron, BP, Eni, Shell and Repsol to operate oil and gas operations in Venezuela. Those companies still have offices in the country and stakes in projects, and are among the main partners of state-run ‌company PDVSA.
The authorization ‌for the oil majors’ operations requires payments for royalties and Venezuelan ​taxes ‌to ⁠go through ​the US-controlled ⁠Foreign Government Deposit Fund.
The other license allows companies around the world to enter contracts with PDVSA for new investments in Venezuelan oil and gas. The contracts are contingent on separate permits from OFAC.
The authorization does not allow transactions with companies in Russia, Iran, or China or entities owned or controlled by joint ventures with people in those countries.
The licenses “invite American and other aligned companies to play a constructive role in supporting economic recovery and responsible investment, ” the US State Department said in a release. Additional authorizations may be issued “as necessary,” it said.
A spokesperson for Chevron, ⁠the only US oil firm currently operating in Venezuela, said the company welcomed ‌the new licenses.
“The new General Licenses, coupled with recent changes ‌in Venezuela’s Hydrocarbons Law, are important steps toward enabling the further development ​of Venezuela’s resources for its people and for advancing ‌regional energy security,” the spokesperson said in a statement.
Eni said it is assessing the opportunities in ‌Venezuela that the authorization opens up.

Oil law reform

The US licenses follow a sweeping reform of Venezuela’s main oil law approved last month, which grants autonomy for foreign oil and gas producers to operate, export and cash sale proceeds under existing joint ventures with PDVSA or through a new production-sharing contract model.
The US has had sanctions on Venezuela since ‌2019 when President Donald Trump imposed them during his first administration. Trump is now seeking $100 billion in investments by energy companies in Venezuela’s oil and gas sector. ⁠US Energy Secretary Chris Wright ⁠said on Thursday, during his second day of a trip to Venezuela, that oil sales from the country since Maduro’s capture have hit $1 billion and would hit another $5 billion in months.
Wright said the US will control the proceeds from the sales until Venezuela stands up a “representative government.” Since last month, the Treasury issued several other general licenses to facilitate oil exports, storage, imports and sales from Venezuela. It also authorized the provision of US goods, technology, software or services for the exploration, development or production of oil and gas in Venezuela.
The Venezuelan government expropriated assets of Exxon Mobil and ConocoPhillips in 2007 under then-President Hugo Chavez. The Trump administration is trying to get those companies to invest in Venezuela as well. At a meeting at the White House with Trump last month, Exxon Mobil CEO Darren Woods said Venezuela was “uninvestable” at ​the moment.
Wright said on Thursday that Exxon, ​which no longer has an office in Venezuela, is in talks with the government there and gathering data about the oil sector. Exxon did not immediately comment.